HUTCHMED says China NMPA accepts sovleplenib wAIHA NDA for priority review
PUBT · 04/29 10:08
Share
Listen to the news
- HUTCHMED secured China NMPA acceptance for sovleplenib NDA in warm antibody autoimmune hemolytic anemia, with priority review.
- NMPA granted Breakthrough Therapy Designation for wAIHA in March 2026.
- Filing targets adult patients with insufficient response to at least one prior glucocorticoid treatment.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604290600PRIMZONEFULLFEED9709354) on April 29, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending